Higher Risk of Severe Breakthrough COVID for Certain HIV Patients
People with HIV and moderate or severe immune suppression contended with a higher risk for severe COVID-19 after breakthrough infections, researchers reported. When compared to people without HIV, the risk of severe breakthrough illness on multivariable analysis was 59% higher in HIV patients with CD4 counts below 350 cells/μL (adjusted hazard ratio [aHR] 1.59, 95% […]
First-Line HIV Treatment Proves Mettle in Pregnant Patients
The HIV agent dolutegravir (Tivicay) was tied to greater viral suppression for pregnant patients with HIV-1, according to a cohort study. Among patients who used dolutegravir during pregnancy, viral suppression at delivery was achieved in nearly 96.7% of participants, reported Kunjal Patel, DSc, of the Harvard T.H. Chan School of Public Health in Boston, and […]
People With Advanced AIDS Benefit From Dolutegravir Treatment
MONTREAL — Patients with advanced HIV/AIDS infections had higher proportion of viral suppression with dolutegravir (Tivicay) treatment versus efavirenz (Sustiva) treatment, a researcher reported. At 48 weeks, 73.9% of the 92 patients assigned to a dolutegravir-based (DTG) regimen achieved viral suppression based on the 200 copies/ml assay versus 47.8% of the 92 patients assigned to […]